This inventor holds 1 USPTO granted patent. Top assignee: Tokyo University of Science Foundation. Active years: 2021.
Company Filing History:
Years Active: 2021
Title: Meiji Itakura: Innovator in Cancer Prognosis Prediction
Introduction
Meiji Itakura is a notable inventor based in Chiba, Japan. He has made significant contributions to the field of medical science, particularly in the area of cancer prognosis prediction. His innovative approach has the potential to improve patient outcomes through more accurate prognostic assessments.
Latest Patents
Meiji Itakura holds a patent for a method that predicts the prognosis of patients with cancer or inflammatory diseases. This novel method involves measuring the expression level of the FROUNT gene in a sample collected from the patient. Since FROUNT is identified as a poor prognostic factor, a lower expression level indicates a better prognosis. Additionally, the method also measures the expression level of CC chemokine receptor/ligand genes, such as CCR2 or CCR5, which are good prognostic factors. A higher expression level of these genes correlates with a better prognosis for the patient. This patent showcases his innovative approach to enhancing cancer treatment strategies.
Career Highlights
Meiji Itakura is affiliated with the Tokyo University of Science Foundation, where he continues to advance his research and development efforts. His work is characterized by a commitment to improving healthcare outcomes through scientific innovation.
Collaborations
He collaborates with esteemed colleagues, including Yuya Terashima and Kouji Matsushima, who contribute to his research endeavors. Their combined expertise fosters a collaborative environment that enhances the quality and impact of their work.
Conclusion
Meiji Itakura's contributions to cancer prognosis prediction exemplify the importance of innovation in medical science. His patented method not only provides valuable insights into patient prognosis but also paves the way for future advancements in cancer treatment.